EF
EFTR.US Effector Therapeutics Inc
- Market cap
- USD 3.76K
- P/E
- -
- P/B
- 0.00x
- ROE
- -4,272.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2024.
Is EFTR.US undervalued?
Graham numberThe Graham number of Effector Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Effector Therapeutics Inc fundamental analysis
No fundamental analysis for Effector Therapeutics Inc yet.
Effector Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Effector Therapeutics Inc
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. It also develops Tomivosert…
Full company profileEffector Therapeutics Inc financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
Effector Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | - | 42.0M | 1.43M | 3.55M | 0.00 | 0.00 |
| Gross Profit | -307K | 42.0M | 1.43M | 3.50M | -111K | -112K |
| Operating Income | -28.6M | 15.8M | -31.9M | -32.4M | -33.8M | -33.6M |
| EBITDA | -28.1M | 16.1M | -31.9M | -32.4M | -32.8M | -32.2M |
| Net Income | -29.7M | 14.2M | 15.8M | -12.9M | -35.8M | -35.3M |
| EPS | -539 | 24 | 9.78 | -7.85 | -16 | -13 |
| Balance Sheet | ||||||
| Total Assets | 5.10M | 16.7M | 54.1M | 29.1M | 20.5M | 27.1M |
| Total Liabilities | 18.9M | 149M | 36.8M | 25.2M | 26.3M | 26.3M |
| Shareholders' Equity | -13.8M | 979K | 17.3M | 3.90M | -5.80M | 827K |
| Cash & Short-term Investments | 3.43M | 15.2M | 49.7M | 26.3M | 18.4M | 25.4M |
| Total Debt | 15.2M | 13.0M | 20.0M | 20.3M | 20.5M | 20.2M |
| Cash Flow | ||||||
| Operating Cash Flow | -27.6M | 13.8M | -24.9M | -25.9M | -29.6M | -29.1M |
| Capital Expenditure | 4.00K | 154K | 42.0K | 192K | 97.0K | 0.00 |
| Free Cash Flow | -27.6M | 13.7M | -24.9M | -26.1M | -29.6M | -29.1M |
| Ratios | ||||||
| ROE | - | 1,451.6% | 91.4% | -331.8% | - | -4,272.8% |
| ROA | -583.7% | 85.1% | 29.2% | -44.5% | -174.3% | -130.2% |
| Net Profit Margin | - | 33.8% | 1,104.8% | -363.8% | - | - |
| Debt to Equity | - | 13.24x | 1.16x | 5.21x | - | 24.48x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Effector Therapeutics Inc dividends
Effector Therapeutics Inc has not paid dividends in the last 5 fiscal years.
Last stock split: 1:25 on Jan 12, 2024.
Who owns Effector Therapeutics Inc
Top funds holding EFTR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| SSgA U.S. Total Market Index Strategy | 69.00 | 0.00% | +40.82% | Jun 2024 |
Top institutions holding EFTR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Proathlete Wealth Management Llc | 12.00 | 0.00% | 0.00% | Jun 2026 |
Effector Therapeutics Inc company profile
- Company name
- Effector Therapeutics Inc
- Ticker
- EFTR.US
- Exchange
- USA Stocks
- Listed since
- Aug 26, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Fiscal year end
- December
- Address
- 142 North Cedros Avenue, Solana Beach, CA, United States, 92075
- Phone
- 858 925 8215
- Website
- effector.com
About Effector Therapeutics Inc
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. It also develops Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. It has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
Effector Therapeutics Inc management
2- Dr. Davide Ruggero Ph.D.Co-Founder and Member of Clinical & Scientific Advisory Board
- Dr. Kevan M. Shokat Ph.D.Co-Founder and Member of Clinical & Scientific Advisory Board